January 1, 2012
By:Formulary staff
Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride
 |
December 1, 2011
By:Formulary staff
Recent FDA action (through November 2011) related to extended release intravitreal insert, vismodegib, apixaban, T-cell vaccine, atorvastatin calcium tablets
|
November 1, 2011
By:Formulary staff
Recent FDA action (through October 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001,cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
|
October 1, 2011
By:Formulary staff
Recent FDA action (through September 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001, cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
|
September 1, 2011
By:Formulary staff
Recent FDA action (through August 2011) related to Zelrix single-use, transdermal sumatriptan patch, Vinorelbine injectable emulsion, canakinumab, KRN5500, Letermovir, radium-223, PSI-938, PLX cells, Alpha-1 antitrypsin
|
August 1, 2011
By:Formulary staff
Recent FDA action (through July 2011) related to Zolpidem tartrate sublingual tablet, Golimumab supplemental biologics license application, Brentuximab vedotin, Dapagliflozin, TMC435 protease inhibitor, resminostat, TM-400
|
July 1, 2011
By:Formulary staff
Recent FDA action (through June 2011) related to oxycodone, aflibercept opthalmic solution, icatibant, eculizumab, asimadoline, anthrax vaccine, SBC-102 enzyme replacement therapy, ciprofloxacin, mitosol, MORAb-004 and MORAb-066, levofloxacin.
|
June 1, 2011
By:Formulary staff
Recent FDA action (through May 2011) related to Augment Bone Graft, crizotinib, DP-b99 development program, regorafenib, MCD-386CR, liver cell infusion of donated human liver cells
|
May 1, 2011
By:Formulary staff
Recent FDA action (through April 2011) related to Liprotamase, Aricept Patch, Telaprevir, Restylane Injectable Gel, VEGF Trap-Eye, Cenderitide, PV-10, INNO-206
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.